> MODG – FSH-CTP is in phase 3 trials now…i have my doubts it will be a success based on what i have seen/heard to date. that alone would taint any future CTP offerings in the pipeline<
MODG admits that its most consequential news flow will be the outcome of the Organon (SGP) FSH-CTP trial. It’s uncomfortable to have an unrelated party controlling your company’s valuation, but MODG knew this would happen when they licensed the residual CTP IP from WUStL.
Why are you pessimistic about this particular trial?
Market Data 
Markets 
AI
